The FDA approved Cobenfy for treating schizophrenia, marking the first new drug class for the disorder in decades.

The U.S. Food and Drug Administration approved Cobenfy, a combination of xanomeline and trospium chloride, for treating schizophrenia in adults on Sept. 26, 2024. The agency described it as the first approved schizophrenia antipsychotic to target cholinergic receptors instead of dopamine receptors, supporting the claim that it represented a new pharmacological approach.fda.govfda.govFDA Approves Drug with New Mechanism of Action for Treatment of Schizophreniaaccessdata.fda.govaccessdata.fda.govReference ID: 5453521+1 more

The phrase “new drug class” is a reasonable shorthand, although the FDA’s more precise wording is “new mechanism of action.” Cobenfy combines a muscarinic agonist with a muscarinic antagonist, and its active therapeutic approach targets muscarinic receptors, including M1 and M4, rather than blocking dopamine D2 receptors. Independent reporting and medical explainers characterized the approval as the first novel schizophrenia treatment in decades, with estimates ranging from more than 30 years to nearly three decades.time.comtime.comFDA Approves the First New Schizophrenia Drug in Decadesmedshadow.orgmedshadow.orgWhat To Know About Cobenfy, First New FDA-Approved Treatment For Schizophrenia...+2 more

The approval was final, not merely a recommendation or advisory-committee decision. The FDA labeling specifies that Cobenfy is indicated for schizophrenia in adults, while the agency’s approval materials document the drug’s clinical and safety review. The claim is therefore supported, with “new drug class” understood as a new treatment mechanism rather than a formal statement about the FDA’s regulatory classification system.accessdata.fda.govaccessdata.fda.govCENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for:fda.govfda.govLa FDA aprueba un medicamento con un nuevo mecanismo de acción para el...+1 more